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with the relevant expertise in managing diabetic foot 
problems, a diabetes nurse specialist, a podiatrist, 
and a tissue viability nurse, with access to other 
specialist services necessary for delivering the care 
outlined in the guideline. 
• The role of the multidisciplinary foot care
 team is to:
-Assess and treat the patient’s diabetes,  
including interventions to minimise the 
patient’s risk of cardiovascular events, and any 
interventions for pre-existing chronic kidney 
disease or anaemia (refer to the NICE guidance 
on chronic kidney disease4 and on managing 
anaemia in people with chronic kidney 
disease5)
-Assess, review, and evaluate the patient’s 
response to initial medical, surgical, and 
diabetes management
-Assess the foot and determine the need for 
specialist wound care, debridement, pressure 
off-loading, and/or other surgical interventions
-Assess the patient’s pain and determine the 
need for treatment and access to specialist pain 
services
-Perform a vascular assessment to determine 
the need for further interventions
-Review the treatment of any infection
-Determine the need for interventions to prevent 
the deterioration and development of Achilles 
tendon contractures and other foot deformities
-Perform an orthotic assessment and treat to 
prevent recurrent disease of the foot
-Refer patients for physiotherapy where 
appropriate
-Arrange discharge planning, which should 
include arranging for the patient to be assessed 
and managed in primary and/or community 
care and followed up by specialist teams 
(refer to the NICE guidance on preventing and 
managing foot problems in type 2 diabetes6).
Information and support for patients
• The patient should have a named contact—who 
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Foot problems that are related to diabetes (“diabetic 
foot” problems) affect a substantial number of people 
with diabetes, and 15% of people with diabetes will 
have a foot ulcer at some point in their lives. Diabetic foot 
ulcers precede more than 80% of amputations in people 
with diabetes and are the most common cause of non- 
traumatic limb amputation in the United Kingdom. Delays 
in diagnosis and management of diabetic foot problems 
increase morbidity and mortality, contribute to a higher 
amputation rate,1 and seriously affect patients’ quality of 
life—for example, by reducing mobility, leading to loss of 
employment, depression, and damage to or loss of limbs. 
Diabetic foot problems have a financial impact on the NHS 
through increased outpatient costs and bed occupancy 
and prolonged stays in hospital.
This article summarises the most recent recommen-
dations in a short clinical guideline from the National 
Institute for Health and Clinical Excellence (NICE) on the 
management of diabetic foot problems in inpatients.2
Recommendations
NICE recommendations are based on systematic reviews 
of best available evidence and explicit consideration of 
cost effectiveness. When minimal evidence is available, 
recommendations are based on the Guideline Develop-
ment Group’s experience and opinion of what constitutes 
good practice. Evidence levels for the recommendations 
are in the full version of this article on bmj.com.
Multidisciplinary foot care team
• Each hospital should have a care pathway for 
patients with diabetic foot problems who need 
inpatient care. This care pathway is for people with 
diabetes who have (a) an ulcer, blister, or break in 
the skin of the foot; (b) inflammation or swelling 
of any part of the foot or any sign of infection; 
(c) unexplained pain in the foot; (d) fracture or 
dislocation in the foot, with no preceding history 
of substantial trauma; or (e) gangrene of all or part 
of the foot.3 The multidisciplinary foot care team 
should consist of healthcare professionals with 
the specialist skills and competencies necessary to 
deliver inpatient care to such patients. The team 
should normally include a diabetologist, a surgeon 
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• Do not routinely use negative pressure wound 
therapy, but consider this in the context of a clinical 
trial or as rescue therapy (when the only other 
option is amputation). 
• Do not offer the following treatments for inpatient 
management, unless as part of a clinical trial:
-Dermal or skin substitutes
-Electrical stimulation therapy, autologous 
platelet-rich plasma gel, regenerative wound 
matrices, and deltaparin
-Growth factors (granulocyte colony stimulating 
factor, platelet derived growth factor, epidermal 
growth factor, and transforming growth factor β)
-Hyperbaric oxygen therapy.
Overcoming barriers
No agreed treatment pathways or service models exist 
for management of diabetic foot problems in inpatients. 
Current practice is thought to vary considerably, owing 
to a range of factors, including differences in the organi-
sation of care from the time of acute care admission to 
discharge. However, prompt identification of diabetic foot 
problems, with appropriate treatment and referral, can 
reduce associated morbidity (including rates of amputa-
tion) and  mortality.1
The NICE recommendations should facilitate the provi-
sion of timely and coordinated care for people with dia-
betic foot problems who are admitted to hospital (either 
for the primary diabetic foot problem or for other reasons 
but who also have a diabetic foot problems). They outline 
what care should be provided and how this should be 
organised, specifying key functions and members of the 
multidisciplinary team.
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reviewed the content. All authors approved the final version. PWB is the 
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may be a member of the multidisciplinary foot care 
team or someone with a specific role as an inpatient 
pathway coordinator—who will follow the inpatient 
care pathway and be responsible for:
-Offering patients information about their 
diagnosis, treatment, and the care and support 
they can expect
-Communicating relevant clinical information, 
including documentation before discharge, 
within and among hospitals and to primary and/
or community care.
Initial examination and assessment 
• Remove the patient’s shoes, socks, bandages 
and dressings and examine their feet for evidence  
of the following and document any identified new 







• Obtain urgent advice from an appropriate specialist 
if any of the following are present:
-Fever or any other signs or symptoms of systemic 
sepsis
-Clinical concern about possible deep seated 
infection (for example, palpable gas)
-Limb ischaemia.
Initial care (within 24 hours)
• For a patient with diabetic foot problems being 
admitted to hospital or already in hospital but with 
newly detected diabetic foot problems, refer to the 
multidisciplinary foot care team within 24 hours of 
the initial examination of the patient’s feet.  
Transfer the responsibility of care to a consultant 
member of the multidisciplinary foot care team if a 
diabetic foot problem is the dominant clinical factor 
for inpatient care.
Investigation of suspected diabetic foot infection
• If osteomyelitis is suspected and initial radiography 
does not confirm the presence of osteomyelitis, 
use magnetic resonance imaging (if this is 
contraindicated, consider white blood cell scanning 
instead).
Management of diabetic foot infection
• Each hospital should have antibiotic guidelines for 
management of diabetic foot infection.
Management of diabetic foot ulcers
• When choosing wound dressings, the 
multidisciplinary foot care team should take into 
account their clinical assessment of the wound, the 
patient’s preference, and the clinical circumstances, 
and they should use wound dressings with the 
lowest acquisition cost.
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The patient presented to his general practitioner nine days 
after surgery with his right eye completely closed and a mild 
intermittent headache. On examination he was clinically 
normovolaemic and had no features of hypopituitarism. He 
had right sided ptosis and a sluggishly reactive and slightly 
dilated right pupil. He had normal abduction but moderate 
restriction of right eye movements in all other directions, 
consistent with an isolated partial right oculomotor nerve 
palsy. His visual acuity and visual fields were normal. 
He was admitted under neurosurgery and a diagnosis of 
 posterior communicating artery aneurysm was considered.
He was hyponatraemic, with a sodium value of 128 
mmol/L (reference range 136-146), and fluids were 
 immediately restricted to 1 L per 24 hours. Magnetic 
 resonance imaging and magnetic resonance angiography 
of the head incidentally showed an enlarged pituitary gland, 
with  diffuse high T1 signal consistent with a sub acute 
pituitary  haemorrhage. He showed no evidence of a pos-
terior communicating artery aneurysm. Pituitary magnetic 
resonance imaging two days later (fig 1A) showed a bilobed 
haemorrhagic intrasellar/suprasellar mass  measuring 
14×13×12 mm, consistent with haemorrhage into a  pituitary 
macroadenoma. The mass extended into the roof of the right 
cavernous sinus, where it abutted the right oculomotor nerve 
at its peripheral aspect.
Despite fluid restriction, the next day (postoperative 
day 10) plasma sodium was 129 mmol/L, urine sodium 
was 55 mmol/L, and urine osmolality was  inappropriately 
high (626 mmol/kg). Plasma cortisol at 9 am was low 
(51 nmol/L; 250-800), free thyroxine was also low (7 
pmol/L; 10-24), and thyroid stimulating hormone was 
normal (0.49 mIU/L; 0.4-4.0), consistent with secondary 
 hypoadrenalism and hypothyroidism. The cortisol result 
was not available until a day later (postoperative day 11), 
and at that stage intravenous (50 mg eight hourly) and later 
oral  hydrocortisone  supplementation was started, after 
which the  hyponatraemia promptly resolved (fig 2). He was 
 maintained on oral  hydrocortisone (15 mg at 8 am, 5 mg at 
3 pm) and daily thyroxine (50 μg).
Further pituitary function tests showed luteinising 
 hormone and follicle stimulating hormone values of 0.4 IU/L 
(2-8) and 1.9 IU/L (2-14), respectively, and total testosterone 
was also low at 1.1 nmol/L (9-38), confirming secondary 
hypogonadism. Prolactin and insulin-like growth factor 1 
were within normal limits. Two days after the markedly low 
cortisol measurement, plasma adrenocorticotrophin was 
normal at 9.2 pmol/L (1-12). During admission his right 
eye symptoms gradually resolved and he was discharged 
14 days after surgery.
The initial non-suppressed plasma adrenocorticotrophin 
concentration raised the possibility of recovery of pituitary 
function and prompted repeat measurement of morning 
cortisol and adrenocorticotrophin on postoperative day 20 
Postsurgical hyponatraemia with ocular 
palsy suggests hypopituitarism from 
haemorrhagic infarction of an unsuspected 
pituitary adenoma
Hyponatraemia is the most common electrolyte  disturbance 
in hospital inpatients. Accurate assessment of the cause 
and appropriate treatment are crucial.1 Hyponatraemia 
after orthopaedic surgery is often caused by hypotonic 
 fluids and factors that increase secretion of antidiuretic 
 hormone, and it resolves with fluid restriction.2  3 But this is 
not always the case, and other causes should be  considered. 
We describe a patient with haemorrhagic infarction of a 
pituitary  adenoma and symptoms of blurred vision from 
 oculoparesis who presented shortly after hip replacement, 
in whom  hyponatraemia was caused by cortisol deficiency.
Case report
A 58 year old man presented with a drooping right eyelid and 
diplopia nine days after a right total hip replacement. He had 
previously been fit and well requiring no regular drugs other 
than analgesia.
Surgery was performed under spinal anaesthesia. Blood 
pressure before surgery was 139/91 mm Hg. Within 30 
minutes of anaesthetic induction his systolic blood pressure 
dropped to 90 mm Hg and was about 70 mm Hg for most of 
the procedure. He received 3 L of crystalloid in theatre and his 
blood pressure was 90/60 mm Hg at the end of surgery, rising 
to 152/95 mm Hg two hours later. He received prophylactic 
aspirin (150 mg daily) but no low molecular weight heparin.
About 10 hours after surgery he developed a severe 
 headache, nausea, and vomiting. He was treated symptomati-
cally and three days later the symptoms had largely resolved. 
On the day of discharge (postoperative day 6), his wife noticed 
drooping of his right eyelid and the patient mentioned that his 
vision had been blurred since surgery. A doctor was consulted 
by telephone and advised that no action was needed.
LESSON OF THE WEEK
Pituitary infarction: a potentially fatal cause of  
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Fig 1 | (A) Magnetic resonance (T1 coronal) imaging of the head 11 days after surgery showing a bilobed 
haemorrhagic intrasellar mass measuring 14×13×12 mm extending into the right cavernous sinus 
where it impinges on the region of the oculomotor nerve (arrow). (B) Magnetic resonance imaging (T1 
coronal) of the pituitary 10 weeks after surgery showing that the high density pituitary lesion had 
reduced in size to 12×4.5 mm. The pituitary stalk is deviated to the left (arrowheads in parts A and B) 
EDITORIAL by Kerr and 
Wierman 
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(after omitting hydrocortisone for 24 hours). Plasma adren-
ocorticotrophin was in the reference range at 10 pmol/L 
(1-12) and cortisol was 515 nmol/L (250-800), confirming 
recovery of the pituitary-adrenal axis. Total thyroxine was 
58 nmol/L (55-140) and thyroid stimulating hormone was 
0.43 mIU/L (0.4-4.0). Treatment with hydrocortisone and 
thyroxine was then stopped.
Ten weeks after discharge his third cranial nerve palsy had 
fully resolved and pituitary function was normal. The patient 
gave no history to suggest a pituitary adenoma before the 
haemorrhagic infarction. Repeat magnetic resonance imag-
ing of the pituitary showed that the mass lesion to the right of 
the midline had greatly reduced in size to 12×4.5 mm (fig 1B).
Discussion
The history, clinical features, and radiological features in 
this case are consistent with haemorrhagic infarction (pitu-
itary apoplexy) of a presumed pre-existing non-functioning 
pituitary adenoma causing reversible anterior hypopitui-
tarism and a transient right third cranial nerve palsy.
Pituitary apoplexy is a potentially life threatening condi-
tion, originally described in 1898 by Bailey.4 Risk factors 
include surgery (particularly coronary artery surgery), 
coagulopathy, and pituitary stimulation tests. However, 
most patients have no obvious precipitating cause and no 
history of pituitary adenoma.5  6 We found two other case 
reports of pituitary apoplexy after routine total hip replace-
ment.2  7 Although the pathogenesis of pituitary apoplexy 
is unclear, hypotension and fluctuations in blood pressure 
have been suggested to increase risk in people undergo-
ing surgery.6 This may be relevant to our patient who had 
prolonged intraoperative hypotension. Immediate man-
agement is with hormone replacement and correction of 
fluid and electrolyte abnormalities. Patients may then be 
managed conservatively or surgically.8
Untreated cortisol deficiency can be fatal, so the condi-
tion must be recognised and treated immediately.8 Head-
ache is the most common presenting symptom. Other 
symptoms and signs include nausea and vomiting, diplo-
pia or visual field deficit, ophthalmoplegia, meningism, 
and reduced consciousness.8  9 Although our patient had 
headache, nausea, and vomiting, these symptoms are com-
monly seen postoperatively and their importance was not 
recognised. Instead he was treated symptomatically, and 
the diagnosis might have been missed if he had not pre-
sented later with a third nerve palsy.
On readmission he was hyponatraemic, and a diagnosis 
of syndrome of inappropriate antidiuretic hormone secre-
tion was made, leading to the initiation of fluid restriction. 
However such a diagnosis requires exclusion of cortisol 
deficiency, either primary or secondary. Patients with 
adrenocorticotrophin deficiency causing secondary corti-
sol deficiency typically have increased plasma concentra-
tions of antidiuretic hormone, a reflection of the normal 
tonic inhibitory action of cortisol on the release of this hor-
mone. The high circulating concentration of antidiuretic 
hormone limits the ability to excrete a water load, which 
places these patients at risk of hyponatraemia, particularly 
if secretion of antidiuretic hormone is further stimulated in 
the postoperative setting and hypotonic fluids are given.1  10 
In our patient the diagnosis of hyponatraemia secondary 
to adrenocorticotrophin deficiency was confirmed by 
the morning cortisol of only 51 nmol/L and supported 
by the response of the hyponatraemia to hydrocortisone 
 replacement (fig 2).
In conclusion, our case highlights the difficulty of diag-
nosing pituitary apoplexy in a patient with an undiagnosed 
pituitary adenoma after surgery because many of the symp-
toms are non-specific. Because surgery is a risk factor for 
pituitary apoplexy and pituitary adenomas are not uncom-
mon (overall prevalence of 17%, 0.2% macroadenomas),11 
maintain a high index of suspicion in patients presenting 
with headache, nausea, and vomiting in association with 
hyponatraemia postoperatively. Do not assume that the low 
sodium value is caused by the syndrome of inappropriate 
antidiuretic hormone secretion and give hydrocortisone 
promptly to those with possible adrenocorticotrophin 
deficiency. Arrange ongoing follow-up so that pituitary 
function can be monitored to check for further pituitary 
dysfunction or, as in this case,  possible resolution of 
 hypopituitarism.
Contributors: HP wrote the report. EE helped manage the patient and 
obtained consent. SS was the specialist endocrinologist and is guarantor. EE 
and SS contributed to the scientific content and proofreading of the paper. 
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A 30 year old pregnant woman going home 
on holiday to Nigeria attends the clinic to 
get a prescription for malaria prevention 
tablets for herself and her two children
What you should cover
Malaria is a potentially life threatening but preventable 
infectious tropical disease, caused by the Plasmodium 
parasite and transmitted by the Anopheles mosquito.
• Ask what type and duration of holiday they plan—
Sub-Saharan Africa is endemic for the most severe 
form of malaria, caused by Plasmodium falciparum. 
Risk increases in rural regions, with high humidity 
(such as during monsoon season), and with length 
of stay in the endemic region.
• Explore health beliefs about immunity to malaria—
People who have survived childhood in malaria 
endemic regions usually have developed immunity. 
However, patients who migrate to non-endemic 
areas often believe that they are still immune 
although this type of immunity declines in the 
absence of regular exposure.
• Advise on the complications of malaria in pregnant 
women and in children—P falciparum malaria in 
pregnant women can cause severe complications 
such as miscarriage and prematurity, and can 
increase maternal morbidity and mortality. 
Children are at risk of serious complications 
such as hypoglycaemia and cerebral malaria. No 
prophylactic regimen provides complete protection, 
and the patient should consider if travel is essential.
What you should do
Advise on the avoidance and prevention of mosquito 
bites—Emphasise the importance of wearing trousers, 
socks, and long sleeved shirts when outside between dusk 
and dawn (when the Anopheles mosquito bites). Insect repel-
lents should be applied to exposed skin using formulations of 
between 30-50% diethyltoluamide (DEET), and may be used 
during pregnancy and on children aged over two months. A 
mosquito bed net impregnated with insecticide should be 
used, tucked in under the mattress, and re-impregnated with 
pyrethroids (such as permethrin) every six months.1
Identify which chemoprophylactic agents are effec-
tive in the region travelled to—Drugs used for malaria 
chemoprophylaxis are chloroquine and proguanil in 
combination, atovaquone and proguanil in combination 
(Malarone), mefloquine, or doxycycline. However, the 
falciparum malaria endemic to all of sub-Saharan Africa 
and to some parts of South East Asia and South America 
is now resistant to chloroquine and use is no longer rec-
ommended in these areas. Either Malarone, mefloquine, 
or doxycycline must be used instead.1 Country specific 
information can be found at the Centers for Disease Con-
trol and Prevention website.
Choose malaria prophylactic drugs appropriate for 
pregnant women (if travel cannot be postponed) or 
children—Chloroquine can be used in children and in 
all trimesters of pregnancy, but is often ineffective owing 
to resistance.1 Doxycycline is contraindicated in pregnant 
women, breastfeeding women, and in children under 12 
years because it can cause staining in growing bones and 
teeth. Malarone can be used for children, but is contrain-
dicated in pregnancy. Mefloquine can be used for children 
and in the last two trimesters of pregnancy. If travel can-
not be postponed, mefloquine may be prescribed in the 
first trimester after taking expert advice (for example, by 
consulting a local travel health specialist, or by calling 
the National Travel Health Network and Centre advice line 
for health professionals, in the UK—see Useful reading). 
Prescribe appropriately for the travel date and 
duration—Mefloquine should be started at least a week 
before travel, but starting two to three weeks before travel 
has the advantage of allowing tolerability to be assessed 
(particularly in those who have not tried it before). Doxy-
cycline and Malarone can be started the day before travel. 
Chloroquine/proguanil should be started a week before 
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travel. Malarone is not licensed for use for more than one 
month in a malarious area, whereas the other drugs can be 
used for longer periods. All the drugs apart from Malarone 
should be continued for four weeks after returning (Malar-
one should be continued for seven days).
Address issues of compliance, side effects, and 
follow-up—The main side effects of malaria prophylac-
tic drugs are summarised in the box. Patients may pre-
fer chloroquine (which is often ineffective) to Malarone 
because chloroquine is much cheaper and is often more 
familiar to patients (as it is much more widely used in 
sub-Saharan Africa). Counsel the patient about specific 
side effects particular to the drug chosen. Mefloquine 
can cause neuropsychiatric side effects1 and should be 
avoided in patients with psychiatric illnesses or epilepsy. 
Instruct the patient to seek immediate medical attention 
if they develop a fever from one week after arrival at their 
destination to 12 months after return. If a patient receives 
antimalarial treatment while on holiday, this should be 
communicated to their GP on their return.
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the submitted work; no financial relationships with any organisations that might 
have an interest in the submitted work in the previous three years; no other 
relationships or activities that could appear to have influenced the submitted work.
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CASE REPORT
A 42 year old man with bilateral 

























Observational study design I
Answer	c	is	true.	
CASE REPORT
A man with hypophosphataemia
1  The patient has tumour induced osteomalacia, with coexisting 
vitamin D insufficiency.
2  The biochemical hallmarks of tumour induced osteomalacia are 
hypophosphataemia, phosphaturia as a result of renal phosphate 
wasting, and a low or inappropriately normal concentration 
of serum calcitriol. Tumours are usually small, benign, slow 
growing, mesenchymal, and difficult to locate, mostly occurring 
in the extremities and craniofacial area. Tumours are localised 
using computed tomography or magnetic resonance imaging, 
but positron emission tomography-computed tomography 
and octreotide scanning may be used if neither of these tests is 
successful. Normalisation of biochemical markers after tumour 
resection confirms the diagnosis. 
3  The basic pathophysiological defect in tumour induced 
osteomalacia is renal phosphate wasting. The tumour 
produces circulating factors called phosphatonins, such 
as fibroblast growth factor 23 (FGF-23). This factor inhibits 
sodium dependent phosphate reabsorption in the proximal 
renal tubules and downregulates 25-hydroxyvitamin 
D-1α-hydroxylase, resulting in hypophosphataemia and 
osteomalacia.
4  The definitive treatment is complete tumour resection. Medical 
treatment comprises replacement of calcitriol, alone or combined 
with phosphate.
ON EXAMINATION QUIZ
Risk factors for stroke
Answer	B	is	correct.
ANATOMY QUIZ
Heart segments on short axis computed 
tomography section
A:  Mid-inferoseptal—right coronary artery
B:  Mid-anteroseptal—left anterior descending artery
C:  Mid-anterior—left anterior descending artery
D:  Mid-anterolateral—left circumflex artery
E:  Mid-inferolateral—left circumflex artery 
